Contact | 
Print version | 
PDF version | 
Send article | 
RSS-Feed
KBI BioPharma Advances Proprietary Bioprocessing Technology Into Applied Biopharmaceutical Development
24 Sep 2004 -
Durham. -KBI BioPharma, Inc., a contract biopharmaceutical process development, production and technology company, announced the advancement of its proprietary Centrifugal Bioreactor (CBR) technology from a research environment into an applied development phase.
Proof-of-principle work has demonstrated that the CBR technology represents a highly productive cell culture system, capable of maintaining extremely high density fluidized bed cultures of both prokaryotic and eukaryotic cells over long periods. The system has been demonstrated to be robust in a laboratory setting and to be compatible with most recognized biopharmaceutical production cell lines. KBI BioPharma will now focus its efforts on demonstrating high productivity of a number of specific recombinant protein and monoclonal antibody products in an applied development environment.
"We are extremely pleased to be able to advance this important biopharmaceutical production technology from a research setting into applications development," said Tony Laughrey, chief executive officer and president of KBI BioPharma. "We believe that the CBR has the potential to dramatically reduce the cost of production for biopharmaceuticals for both clinical trial quantities and market supply and may represent a paradigm changing approach to production of these important molecules."
All future CBR development work will be undertaken within laboratories at KBI BioPharma's campus in Durham, N.C., where the company's established biopharmaceutics platform will be leveraged to facilitate rapid progression through applications development. KBI BioPharma's highly experienced development staff, cGMP infrastructure, state-of-the-art analytical capabilities and quality expertise will be utilized in support of further development under the direction of Dr. Firoz Mistry, vice president cell culture and fermentation operations.
KBI BioPharma's CBR technology applies advanced fluidized bed methodology to allow cells producing recombinant therapeutic and vaccine products to be immobilized at very high densities without use of membranes or other solid support or retention devices. CBR technology allows true continuous production of uniform high quality product at significantly lower capital and operating cost. KBI BioPharma will execute research collaborations with a limited number of companies developing recombinant proteins or monoclonal antibodies to demonstrate performance of the CBR technology in production of specific products. Interested parties can contact KBI BioPharma's business development group by visiting www.kbibiopharma.com.
Top